Cargando…

Anti-Tumor Activity of Novel Nimotuzumab-Functionalized Gold Nanoparticles as a Potential Immunotherapeutic Agent against Skin and Lung Cancers

The epidermal growth factor receptor (EGFR) is vital for many different types of cancer. Nimotuzumab (NmAb), an anti-EGFR monoclonal antibody (mAb), is used against some of EGFR-overexpressed cancers in various countries. It targets malignant cells and is internalized via receptor-mediated endocytos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Anisuzzman, Mohammad, Komalla, Varsha, Tarkistani, Mariam Abdulaziz M., Kayser, Veysel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10456021/ https://www.ncbi.nlm.nih.gov/pubmed/37623652 http://dx.doi.org/10.3390/jfb14080407

Ejemplares similares

Recent Advances in the Use of Iron–Gold Hybrid Nanoparticles for Biomedical Applications
por: Tarkistani, Mariam Abdulaziz M., et al.
Publicado: (2021)

Synthesis and Enhanced Cellular Uptake In Vitro of Anti-HER2 Multifunctional Gold Nanoparticles
por: Cruz, Esteban, et al.
Publicado: (2019)

Nimotuzumab, an Anti-EGFR Monoclonal Antibody, in the Treatment of Nasopharyngeal Carcinoma
por: Liang, Renba, et al.
Publicado: (2021)

Nimotuzumab as a radiosensitizing agent in the treatment of high grade glioma: challenges and opportunities
por: Diaz-Miqueli, Arlhee, et al.
Publicado: (2013)

Evaluation of nimotuzumab Fab(2) as an optical imaging agent in EGFR positive cancers
por: Bernhard, Wendy, et al.
Publicado: (2023)

Immunotherapeutic Agents for Intratumoral Immunotherapy
por: Shyr, Chih-Rong, et al.
Publicado: (2023)

Nimotuzumab for COVID-19: case series
por: Abdo Cuza, Anselmo A, et al.
Publicado: (2021)

Nimotuzumab increases the anti-tumor effect of photodynamic therapy in an oral tumor model
por: Bhuvaneswari, Ramaswamy, et al.
Publicado: (2015)

Cancer Immunotherapy and Application of Nanoparticles in Cancers Immunotherapy as the Delivery of Immunotherapeutic Agents and as the Immunomodulators
por: Debele, Tilahun Ayane, et al.
Publicado: (2020)

Gold(iii) promoted formation of dihydroquinazolinones: double X–H activation by gold
por: Kadiyala, Veerabhushanam, et al.
Publicado: (2020)

Pembrolizumab: An Immunotherapeutic Agent Causing Endocrinopathies
por: Chaudry, Abdul, et al.
Publicado: (2020)

Profile of nimotuzumab in the treatment of high-grade glioma
por: Yang, Qun-ying, et al.
Publicado: (2015)

Nimotuzumab for Patients With Inoperable Cancer of the Head and Neck
por: Crombet Ramos, Tania, et al.
Publicado: (2020)

Upregulation of HLA Class I Expression on Tumor Cells by the Anti-EGFR Antibody Nimotuzumab
por: Garrido, Greta, et al.
Publicado: (2017)

Antimicrobial Peptides As Biologic and Immunotherapeutic Agents against Cancer: A Comprehensive Overview
por: Roudi, Raheleh, et al.
Publicado: (2017)

Human Neutrophil Peptide 1 as immunotherapeutic agent against Leishmania infected BALB/c mice
por: Abdossamadi, Zahra, et al.
Publicado: (2017)

GM-CSF augmented the photothermal immunotherapeutic outcome of self-driving gold nanoparticles against a mouse CT-26 colon tumor model
por: Dai, Jie, et al.
Publicado: (2023)

Immunotherapeutic Intervention against Sarcomas
por: Pedrazzoli, Paolo, et al.
Publicado: (2011)

Irradiation to Improve the Response to Immunotherapeutic Agents in Glioblastomas
por: Nesseler, Jean Philippe, et al.
Publicado: (2018)

Gold Nanoparticles Encapsulated Resveratrol as an Anti-Aging Agent to Delay Cataract Development
por: Chen, Qifang, et al.
Publicado: (2022)

Nimotuzumab in the Treatment of Inoperable Esophageal Tumors of Epithelial Origin
por: González Fernández, Sandra, et al.
Publicado: (2022)

Combining Gold Nanoparticles with Other Radiosensitizing Agents for Unlocking the Full Potential of Cancer Radiotherapy
por: Alhussan, Abdulaziz, et al.
Publicado: (2021)

Gold Nanoparticles: An Efficient Antimicrobial Agent against Enteric Bacterial Human Pathogen
por: Shamaila, Shahzadi, et al.
Publicado: (2016)

Therapeutic potential of nimotuzumab PEGylated-maytansine antibody drug conjugates against EGFR positive xenograft
por: Hartimath, Siddesh V., et al.
Publicado: (2019)

Anti-CD24 bio Modified PEGylated Gold Nanoparticles as Targeted Computed Tomography Contrast Agent
por: Ghaziyani, Mona Fazel, et al.
Publicado: (2018)

Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent
por: Wang, Pengju, et al.
Publicado: (2017)

Hepatocellular carcinoma treated with anti-epidermal growth factor receptor antibody nimotuzumab: A case report
por: Song, Peng, et al.
Publicado: (2017)

Immunotherapeutic and their immunological aspects: Current treatment strategies and agents
por: Jain, Mayank, et al.
Publicado: (2022)

Bioinformatic Analysis of Hepatocellular Carcinoma Cell Lines to the Efficacy of Nimotuzumab
por: Wang, Yu, et al.
Publicado: (2021)

Functional Gold Nanoparticles as Potent Antimicrobial Agents against Multi-Drug-Resistant Bacteria
por: Li, Xiaoning, et al.
Publicado: (2014)

NKT Cells as an Ideal Anti-Tumor Immunotherapeutic
por: Fujii, Shin-ichiro, et al.
Publicado: (2013)

Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status
por: Chong, Dawn Q, et al.
Publicado: (2015)

An overview of some potential immunotherapeutic options against COVID-19
por: Bayat, Maryam, et al.
Publicado: (2021)

Synthetic glycolipid activators of natural killer T cells as immunotherapeutic agents
por: Carreño, Leandro J, et al.
Publicado: (2016)

Gastrointestinal Adverse Effects of Immunotherapeutic Agents: A Systematic Review
por: Dahiya, Dushyant Singh, et al.
Publicado: (2020)

Mushroom-Derived Bioactive Molecules as Immunotherapeutic Agents: A Review
por: Patel, Dinesh K., et al.
Publicado: (2021)

The emerging role of nimotuzumab in the treatment of non-small cell lung cancer
por: Boland, William, et al.
Publicado: (2010)

EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab's Clinical Effects
por: Perez, Rolando, et al.
Publicado: (2011)

Prostate specific antigen change after administration of nimotuzumab in prostate cancer
por: Chaiyasit, Kamon, et al.
Publicado: (2013)

Nimotuzumab combined with concurrent chemoradiotherapy benefits patients with advanced nasopharyngeal carcinoma
por: Li, Zhanzhan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_4u620lpg66jqsbk312iohl92b1